Gadolinium Deposition and Chronic Toxicity

Abstract

Clinicians, radiologists, and patients should be aware of the most up-to-date data on the risks of gadolinium-based contrast agent (GBCA) administration. In this review, we discuss in vivo gadolinium retention, particularly brain tissue retention, and potential toxic effects. GBCA pharmacokinetics and biodistribution are reviewed briefly. Based on the more recent published literature and society guidelines, general safety recommendations for clinical practice are provided.

Keywords: GBCAs; Gadolinium; Gadolinium deposition disease; Gadolinium retention; Gadolinium storage condition; MR imaging.